非小细胞肺癌50年进展:新同事的临床指南
国际肺癌研究协会传播委员会发表综述,总结过去50年肺癌在预防、分期、筛查、诊断、治疗及支持治疗方面的主要进展,旨在为临床医生提供当前诊疗标准的「生存指南」。
要点
- 过去50年肺癌诊疗从分子分型、低剂量CT筛查到治疗选择不断扩展。
- 支持治疗与临终关怀方法也取得实质性改善。
- 本文汇总了预防至支持治疗各领域主要问题的解决历程。
核心结论
- 过去50年肺癌诊疗取得显著进展,涵盖分子分型、低剂量计算机断层扫描筛查生存获益及不断扩展的治疗选择,支持治疗与临终关怀也大幅改善。
研究设计与样本
- 国际肺癌研究协会传播委员会发表的最新综述,总结过去50年肺癌主要问题的解决历程。
主要发现
- 肺癌诊疗从生物学理解有限、筛查无获益证据、治疗获益边际,演进至分子分型、低剂量计算机断层扫描筛查生存获益及治疗选择稳步扩展的时代。
- 支持治疗与临终关怀方法取得实质性改善。
临床怎么用
- 本文旨在作为肺癌诊疗新标准的「生存指南」,面向临床医生及其他相关利益方,将当前诊疗标准置于过去50年进展的背景中。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the past 50 years, we have seen a dramatic evolution in thoracic oncology. We have gone from a time of limited understanding of the biology of lung cancer, no demonstrated benefits for screening, and marginal benefits from therapy to an era of molecular profiling, survival benefits from low-dose computed tomography screening, and a steadily expanding list of therapeutic options. Coupled with these advances have been substantial improvements in approaches related to supportive care and end of life. In this state-of-the-art article, the Communications Committee of the International Association for the Study of Lung Cancer presents a comprehensive summary of how some of the major questions in lung cancer were addressed during the last 50 years: from prevention to staging, screening, diagnostics, therapeutics, and supportive care. This is intended to serve as a "survival guide" for new standards in lung cancer care aimed at clinicians and other interested stakeholders, which places these current standards of care in the context of progress in the last 50 years.
引用
- Naidoo J, Niroula A, Uprety D, et al. 50 Years of Progress in NSCLC: A New Fellow's Guide in the Clinic. J Thorac Oncol. 2025. PMID: 40617395. doi:10.1016/j.jtho.2025.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。